Entera Bio Ltd. · NASDAQ:ENTX

Entera Bio — Investor Presentation (September 2023)

36 slides from Entera Bio's investor presentation, September 2023

  1. Slide 1: Entera Bio Corporate Presentation

    Slide 1: Entera Bio Corporate Presentation

    Entera Bio Corporate Presentation September 2023

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer Various statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business

  3. Slide 3: Leader in Orally Administered Protein Therapies

    Slide 3: Leader in Orally Administered Protein Therapies

    Entera Bio: Leader in Orally Administered Protein Therapies • Proprietary oral delivery technology enables first-in-class, mini tablet formats of protein and peptide replacement therapies • Underserved conditions where oral administration can significantly shift treatment outcomes, versus standard o

  4. Slide 4: Experienced Leadership Team

    Slide 4: Experienced Leadership Team

    Experienced Leadership Team 20+ years of biotech C-level leadership and wall street experience; Previously co- Miranda Toledano, MBA founder/COO/CFO TRIGR (Acquired by Compass Therapeutics, Nasdaq: CMPX); Head of HC Chief Executive Officer Investment Banking at MLV/FBR (Acquired B Riley); VP Investm

  5. Slide 5: Clinical & Scientific Advisory Board

    Slide 5: Clinical & Scientific Advisory Board

    Clinical & Scientific Advisory Board Vice-Chair, Department of Medicine for International Research and Education; Chief, Emeritus, of the Division of Professor John P. Bilezikian Endocrinology; Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center Professor

  6. Slide 6: Oral Bioavailability Challenges: Entera Proprietary Oral Delivery Platform

    Slide 6: Oral Bioavailability Challenges: Entera Proprietary Oral Delivery Platform

    Oral Bioavailability Challenges: Entera Proprietary Oral Delivery Platform Most therapeutic peptides/proteins are SBTI Stabilizes the Protein Administered via IV, SC or IM Injections due to Stability of Peptide in solution in presence of Trypsin proteolytic degradation, variability and lack of 100 P

  7. Slide 7: Entera Oral Delivery of GLP-2 Analog (Teduglutide) Tablets

    Slide 7: Entera Oral Delivery of GLP-2 Analog (Teduglutide) Tablets

    Entera Oral Delivery of GLP-2 Analog (Teduglutide) Tablets Published May 2023 Oral Tedaglutide Control formulation Oral Tedaglutide Control formulation Teduglutide dose 0.7mg 0.7mg Cmax 17.1 ng/ml 0.6 ng/ml Formulation excipients SNAC+SBTI Mannitol CV% Cmax 19.6% 200% Dosage form Minitablets Minitab

  8. Slide 8: EB613 (oral PTH (1-34), teriparatide)

    Slide 8: EB613 (oral PTH (1-34), teriparatide)

    EB613 (oral PTH (1-34), teriparatide) First Daily Oral Osteoanabolic Mini Tabs for High-Risk, No Prior Fracture Post-Menopausal Women

  9. Slide 9: Osteoporosis Results From An Imbalance In The Bone Remodeling Cycle

    Slide 9: Osteoporosis Results From An Imbalance In The Bone Remodeling Cycle

    Osteoporosis Results From An Imbalance In The Bone Remodeling Cycle That Occurs When Bone Resorption Outpaces Bone Formation Bone Density Healthy vs. Osteoporotic Osteoporosis and the Bone Remodeling Cycle The Bone Remodeling Cycle can be separated into two distinct processes: Resorption (osteoclast

  10. Slide 10: Globally, Osteoporosis Afflicts More Women than Heart Attack, Stroke, and Breast Cancer

    Slide 10: Globally, Osteoporosis Afflicts More Women than Heart Attack, Stroke, and Breast Cancer

    Globally, Osteoporosis Afflicts More Women than Heart Attack, Stroke, and Breast Cancer Combined Japan 15 million patients with osteoporosis 20% women over 50 at vs. 5% of men at risk of fracture European Union5 China7 Osteoporosis 70 million patients with osteoporosis United States1-4 25.5 million

  11. Slide 11: Osteoporosis and Menopause

    Slide 11: Osteoporosis and Menopause

    Osteoporosis and Menopause Menopausal transition period Secreted estrogen level Dyslipidemia, hypertension Endometriosis Schematic showing • As hormones change to accommodate Osteoporosis changes in estrogen level with age, normal menopausal changes, estrogen and subsequent disease patterns.3 levels

  12. Slide 12: Healthcare Providers Use T-score BMD Classifications to Drive Therapy Selection

    Slide 12: Healthcare Providers Use T-score BMD Classifications to Drive Therapy Selection

    Healthcare Providers (Endo, PCP, GYN) Typically Use T-score BMD Classifications, Patient Fracture History and Preference To Drive Therapy Selection • Injections deter many patients from using extremely effective PTH therapy, contributing to a treatment gap in high-risk patients T-Score Scale • An or

  13. Slide 13: Current Osteoporosis Pharmacologic Treatment: Anti-Resorptive & Anabolic Options

    Slide 13: Current Osteoporosis Pharmacologic Treatment: Anti-Resorptive & Anabolic Options

    Current Osteoporosis Pharmacologic Treatment Is Segmented Into: Anti-Resorptive & Anabolic Options Stop or slow bone loss Osteoporosis Diagnosis Bone forming Antiresorptive Anabolic ENTERA BIO RANK-Ligand Monoclonal PTH receptor Bisphosphonates Estrogen*/HRT SERMs** Calcitonin Inhibitor Antibodies a

  14. Slide 14: EB613 Phase 2 Results

    Slide 14: EB613 Phase 2 Results

    EB613 Phase 2 Results A Six-Month Study of Oral PTH in Postmenopausal Women with Low Bone Mass – 6 Month Bone Mineral Density (BMD) Results

  15. Slide 15: EB613 Phase 2 Clinical Trial Design

    Slide 15: EB613 Phase 2 Clinical Trial Design

    EB613 Phase 2 Clinical Trial Design in High Risk, No Prior Fracture Post- Menopausal Women with Osteoporosis • 6-Month, Randomized Dose-Ranging Placebo-Controlled Study in Post-Menopausal Women with Osteoporosis • Conducted at 4 sites in Israel between June 2019 and May 2021; Final enrollment = 161

  16. Slide 16: EB613: Met Pharmacodynamic Endpoint, Bone Turnover Biomarkers

    Slide 16: EB613: Met Pharmacodynamic Endpoint, Bone Turnover Biomarkers

    EB613: Met Pharmacodynamic Endpoint, Bone Turnover Biomarkers • Primary Endpoint: Statistically significant increases in P1NP (key anabolic marker) at Month 1 (p<0.001), Month 2 (p<0.005) and Month 3 (p<0.05), respectively for the 2.5 mg EB613 dose group • Statistically significant decrease in Serum

  17. Slide 17: EB613 Mini Tablets Had Significant Dose Response Across BMD, PK and PD

    Slide 17: EB613 Mini Tablets Had Significant Dose Response Across BMD, PK and PD

    EB613 Mini Tablets Had Significant Dose Response Across BMD, PK and PD Concentration of hPTH(1-34) in plasma 400 15min post-dose (mean± SE)(pg/ml) EB613 (a.k.a. EBP05, hPTH(1-34) min-tablets) showed a PTH (1-34) 350 linear dose response across PTH exposure, P1NP R² = 0.9961 300 biomarker and BMD Mea

  18. Slide 18: EB613 Increased BMD at All Major Skeletal Sites

    Slide 18: EB613 Increased BMD at All Major Skeletal Sites

    EB613 Increased BMD at All Major Skeletal Sites at 6 Months (TH, LS, FN) Placebo adjusted Lumbar Spine BMD • Patients on placebo had decreases in 6 BMD score across all skeletal sites at % change from Day 1 Patients on Placebo had a 0.16% Decrease in LS BMD at 6 months 5 6 months 4 3 2 • EB613 Lumba

  19. Slide 19: EB613 Phase 2 Safety Profile

    Slide 19: EB613 Phase 2 Safety Profile

    EB613 Phase 2 Safety Profile Consistent with PTH Targeted Injectables • Adverse event profile - similar to AE profile reported with Forteo and typical of orthostatic hypotension • EB613 not associated with serum calcium increases or hypercalcemia adverse events • 2.5 mg dose with titration (1.5mg f

  20. Slide 20: Osteoporosis Market Overview

    Slide 20: Osteoporosis Market Overview

    Osteoporosis Market Overview Sales and Current Prescription Trends

  21. Slide 21: Anabolic Treated Patients Comprise Less Than 10% of Treated Osteoporosis Patients

    Slide 21: Anabolic Treated Patients Comprise Less Than 10% of Treated Osteoporosis Patients

    Anabolic Treated Patients Comprise Less Than 10% of Currently Treated Osteoporosis Patients, Mostly Very High Risk Patients with Prior Fracture (Endocrinologists and PCPs form majority of the current prescribing base) Population Treated Share of Osteoporosis Treated by Class of Osteoporosis Medicati

  22. Slide 22: EB613 Poised To Create A Paradigm Shift In Osteoporosis Treatment

    Slide 22: EB613 Poised To Create A Paradigm Shift In Osteoporosis Treatment

    EB613 Poised To Create A Paradigm Shift In The Treatment of Osteoporosis To Be The First Daily Tablet Anabolic Therapy Forteo® Tymlos® Evenity® Prolia® Bisphosphonates Entera Key Product Needs (Lilly) (Radius) (Amgen) (Amgen) (generics) EB613 Treats Osteoporosis Rebuilds Bone Oral Dosing ENTERA BIO

  23. Slide 23: EB613 Phase 3 Plan and Overview of FDA Process

    Slide 23: EB613 Phase 3 Plan and Overview of FDA Process

    EB613 Phase 3 Plan and Overview of FDA Process

  24. Slide 24: EB613 Phase 3 Clinical Trial Design

    Slide 24: EB613 Phase 3 Clinical Trial Design

    EB613 Phase 3 Clinical Trial Design • Designed with FDA Concurrence (Pursuant to Type C and Type D Meeting) • A Single Global Phase 3, 24-Month Double-Blind, Placebo-Controlled Registrational Study • Total Hip (TH) BMD as Primary Endpoint Screening 24 M Treatment Endpoints Primary – 2:1 Randomizatio

  25. Slide 25: EB613 Phase 3 Clinical Trial Design Uses ASBMR-FNIH STEs

    Slide 25: EB613 Phase 3 Clinical Trial Design Uses ASBMR-FNIH STEs

    EB613 Phase 3 Clinical Trial Design Uses ASBMR-FNIH STEs • The primary endpoint agreed upon is Mean Change from Baseline in Total Hip BMD of EB613 vs. placebo at 24 months. As a key secondary endpoint, Entera intends to assess this using the pre-defined, published ASBMR- FNIH Surrogate Threshold Eff

  26. Slide 26: Change in Total Hip BMD - Primary Endpoint Analysis for Phase 3

    Slide 26: Change in Total Hip BMD - Primary Endpoint Analysis for Phase 3

    Change in Total Hip BMD - Primary End Point Analysis for Phase 3 EB613 (Titrated 2.5mg dose, Phase 2) vs. FNIH Surrogate Threshold Effects (STEs*) Forteo® (Leder Study) at 6 Months at 24 Months to be Used in EB613 Phase 3 Total Hip BMD 2.5 % BMD Change vs Placebo 2.07 2.13 2 1.83 ENTERA BIO 1.5 1.42

  27. Slide 27: Brief Historical Overview of EB613 Regulatory Trajectory

    Slide 27: Brief Historical Overview of EB613 Regulatory Trajectory

    Brief Historical Overview of EB613 Regulatory Trajectory From End of Phase 2 Mtg 2022 to Date EB613*: Potentially the First Daily Oral PTH Mini Tablets, OsteoAnabolic Treatment for Osteoporosis • June 2021: Phase 2 study met biomarker/PD (P1NP, CTX) and 6-month BMD** endpoints in post- menopausal wo

  28. Slide 28: EB613 Positioning

    Slide 28: EB613 Positioning

    EB613 Positioning • PTH receptor activation is a validated mechanism of action for treating osteoporosis, as evidenced by FDA/EMA approvals of efficacious agents such as the injectable Forteo® (2002) and Tymlos® (2017) • In this silent disease, patients remain reluctant to take daily injections even

  29. Slide 29: EB612 Oral PTH (1-34) for Hypoparathyroidism

    Slide 29: EB612 Oral PTH (1-34) for Hypoparathyroidism

    EB612 Oral PTH (1-34) First Daily Oral PTH Mini Tablet Peptide Replacement Therapy for the Treatment of Hypoparathyroidism

  30. Slide 30: Hypoparathyroidism: PTH Orphan Indication with Sub-Par Clinical Care

    Slide 30: Hypoparathyroidism: PTH Orphan Indication with Sub-Par Clinical Care

    Hypoparathyroidism: PTH Orphan Indication with Sub-Par Clinical Care Hypoparathyroidism Overview Unmet Need and Market Opportunity Hypoparathyroidism (HypoPT) is a rare condition in which the How many people are affected by HypoPT? parathyroid glands fail to produce sufficient levels of • Approximat

  31. Slide 31: Hypoparathyroidism

    Slide 31: Hypoparathyroidism

    Hypoparathyroidism Uninsured <45 years Male 25% 16% 26% Hypoparathyroidism in the United States1,2 ENTERA BIO >45 years Female Insured 74% 75% 84% Symptom severity despite use of calcium and vitamin D2 • Published studies have reported the prevalence of chronic hypoparathyroidism to range from 6.4 t

  32. Slide 32: EB612: Summary of PK and Pilot Phase 2 Data

    Slide 32: EB612: Summary of PK and Pilot Phase 2 Data

    EB612: Potentially First Oral PTH (1-34) Daily Tablets for Hypoparathyroidism, Summary of PK and Pilot Phase 2 Data Study Design Results Efficacy: Oral Calcium Intake Phase 2a, open-label, multicenter pilot Per Protocol Analysis (N=15) study to evaluate the safety, tolerability and 42% reduction (p=

  33. Slide 33: Entera Next Generation Platform – Current Phase 1 PK/PD Clinical Trial

    Slide 33: Entera Next Generation Platform – Current Phase 1 PK/PD Clinical Trial

    Entera Next Generation Platform – Current Phase 1 PK/PD Clinical Trial • During 2022, we completed pre-clinical work on proprietary new generations of our oral peptide delivery platform • Potential for curbed dosing of mini tablets across more complex therapeutic proteins and follow-on candidates fo

  34. Slide 34: EB612 Positioning

    Slide 34: EB612 Positioning

    EB612 Positioning • EB612 is potentially the first oral PTH (1-34) daily tablet peptide replacement therapy for the treatment of hypoparathyroidism • Hypoparathyroidism (HypoPT) is a rare condition in which the parathyroid glands fail to produce sufficient levels of Parathyroid hormone (PTH) • Pilot

  35. Slide 35: Key Recent and Near-Term Milestones

    Slide 35: Key Recent and Near-Term Milestones

    Key Recent and Near-Term Milestones EB613 EB613 EB612 EB613 EB613 ENTERA BIO ✓ FDA Type C FDA Type D PK Data from 2nd Update from FDA Phase 3 Pivotal Meeting onPhase Meeting on Generation Platform ASBMR-FNIH Study Initiation ✓ 3 Design (Executed, Revised Phase 3 Protocol for EB613 and Mini Tab Formu

  36. Slide 36: Thank You

    Slide 36: Thank You

    Thank You Contact: Entera Bio: Ms. Miranda Toledano Chief Executive Officer Email: miranda@enterabio.com

Source: Internet Archive copy of enterabio.com

More decks from Entera Bio Ltd.

All 10 Entera Bio decks